Lumida
/HLF
⌘K
Herbalife Ltd

Herbalife Ltd

HLF
$12.02USD↓-2.12%-0.26 today

MARKET CAP

1.3B

P/E (TTM)

5.2x

FWD P/E

—

DAY RANGE

$12 – $13

52W RANGE

$8
$20

AI Summary

Stalk
TrimMedium

HLF is consolidating near recent lows under declining long-term moving averages, indicating that supply remains dominant and upside conviction is lacking. With price below the 50- and 200-day averages and no active reversal patterns, the medium-term bias is bearish. Execution should be deferred: focus on selling into rallies toward the EMA/50 DMA cluster and the 200-day SMA, watching for rejection and normalized volume to confirm supply. A sustained breakout above these averages on strength would invalidate the bearish thesis and require reevaluation.

  • ↑Net sales +5.4% YoY to $1.3B in Q2, fourth consecutive growth
  • ↑FCF yield >23% with $147M operating cash flow in H1 2026
  • ↓Net loss $26M in Q2 due to debt extinguishment, underscoring profitability strain
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Herbalife Ltd. (NYSE: HLF) is a global nutrition company primarily known for its dietary supplements and wellness products, primarily distributed through a vast network of independent distributors. Currently a leader within the personalized nutrition segment, Herbalife is evolving its product offerings to align with growing consumer demands for personalized health solutions. The company leverages technology and science to enhance user experience, establishing a competitive foothold in the health and wellness market.

Bull says

  • ↑Net sales +5.4% YoY to $1.3B in Q2, fourth consecutive growth
  • ↑FCF yield >23% with $147M operating cash flow in H1 2026
  • ↑BionicGo launch taps into $34B personalized nutrition market
  • ↑Earnings yield of 2.46 signals attractive returns vs. price
  • ↑Positive factor scores highlight strong quality and momentum

Bear says

  • ↓Net loss $26M in Q2 due to debt extinguishment, underscoring profitability strain
  • ↓Gross margin down 30 bps YoY to 77.7% amid rising input costs
  • ↓Leverage ratio at 1.8 increases vulnerability to rate hikes
  • ↓P&G’s Thorne acquisition intensifies competition in personalized nutrition
  • ↓Negative profitability and growth factors point to efficiency and expansion challenges
  • ↓Q3 sales growth guidance of 0.5%–4.5% YoY suggests muted near-term momentum

Investment themes with HLF

Food Products↓ -1.01%

ADM · CTVA · KR

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-02-2025neutral

Transcript signals

Bull points

  • Today, I'm excited to report that we are beginning to see positive results from these efforts.
  • At this landmark event, we ushered in a new era for Herbalife.
  • and you'll see a little bit more net sales coming from that.

Bear points

  • So we are supporting them. We are also making sure we're paying attention where we need to pay attention so that when the time comes, if they want more support or if we think that we need to pivot a little bit faster or stronger into something, we'll be able to do that. But for the time being, we're not seeing the huge demand that I think some companies are feeling that they are seeing or are reading and that they're making these big moves.
  • So we are supporting them. We are also making sure we're paying attention where we need to pay attention so that when the time comes, if they want more support or if we think that we need to pivot a little bit faster or stronger into something, we'll be able to do that. But for the time being, we're not seeing the huge demand that I think some companies are feeling that they are seeing or are reading and that they're making these big moves.
  • last year's first quarter adjusted EBITDA benefited from approximately $9 million of China grant income that did not repeat in the current year.
Read full transcript analysis ›